Recent News

• 04.25.2025 - Dennis Kennedy
• 04.25.2025 - Dennis Kennedy
• 04.18.2025 - Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 04.18.2025 - Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 04.02.2025 - Evan Seigerman
• 04.02.2025 - Evan Seigerman
• 03.25.2025 - FDA Grants Priority Review for Biologics License Application (BLA) and EMA Accepts Marketing Authorisation Application (MAA) for Apitegromab as a Treatment for Spinal Muscular Atrophy
• 03.25.2025 - FDA Grants Priority Review for Biologics License Application (BLA) and EMA Accepts Marketing Authorisation Application (MAA) for Apitegromab as a Treatment for Spinal Muscular Atrophy
• 03.16.2025 - Scholar Rock Presents New Phase 3 SAPPHIRE Data at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
• 03.16.2025 - Scholar Rock Presents New Phase 3 SAPPHIRE Data at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference

Recent Filings

• 04.11.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.11.2025 - DEF 14A Other definitive proxy statements
• 04.11.2025 - ARS Annual Report to Security Holders
• 03.25.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.25.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.24.2025 - 144 Report of proposed sale of securities
• 03.21.2025 - 3 Initial statement of beneficial ownership of securities
• 03.21.2025 - 8-K Current report
• 03.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.17.2025 - 144 Report of proposed sale of securities